{"id":"NCT00322556","sponsor":"CSL Behring","briefTitle":"Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)","officialTitle":"A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2006-05-08","resultsPosted":"2012-10-26","lastUpdate":"2012-10-26"},"enrollment":55,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Agammaglobulinemia","IgG Deficiency","Common Variable Immunodeficiency"],"interventions":[{"type":"DRUG","name":"Immunoglobulins Intravenous (Human)","otherNames":[]}],"arms":[{"label":"IgPro10","type":"EXPERIMENTAL"}],"summary":"The objectives of this trial are the assessment of safety and efficacy of IgPro10 in patients with PID, and the assessment of tolerability of high infusion rates. To demonstrate safety, the number of infusions temporally associated with AEs, the rate, severity and relationship of all AEs and the vital sign changes during each infusion will be evaluated.","primaryOutcome":{"measure":"The Proportion of Infusions With One or More Temporally-associated Adverse Events (AEs).","timeFrame":"During each infusion, and within 48 or 72 hours after the end of each infusion.","effectByArm":[{"arm":"IgPro10","deltaMin":0.073,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["20217199"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":55},"commonTop":["Headache","Sinusitis","Cough","Nausea","Diarrhea"]}}